Dexpramipexole attenuates myocardial ischemia/reperfusion injury through upregulation of mitophagy

Lu Tang,Yun-Peng Li,Juan Hu,Ai-Hua Chen,Yingli Mo,Yun-peng Li,Ai-hua Chen
DOI: https://doi.org/10.1016/j.ejphar.2021.173962
IF: 5.195
2021-05-01
European Journal of Pharmacology
Abstract:<p>Reperfusion causes undesirable damage to the ischemic myocardium while restoring the blood flow. In this study, we evaluated the effects of dexpramipexole (DPX) on myocardial injury induced by ischemia/reperfusion (I/R) <em>in-vivo</em> and the hypoxia/reoxygenation (HR) <em>in-vitro</em> and examined the functional mechanisms of DPX. DPX protected cells against H/R-induced mitochondrial dysfunction and prevented H/R damage. Both myocardial infarct size and tissue damage due to I/R was reduced upon DPX treatment. We discovered that DPX enhanced mitophagy <em>in-vivo</em> and <em>in-vitro</em>, which was accompanied by enhanced expression of PINK1 and Parkin. Knock-down of PINK1 and Parkin by specific siRNAs reversed DPX-induced inhibition of myocardial I/R injury. These findings suggest that DPX might protect against myocardial injury via PINK1 and Parkin.</p>
pharmacology & pharmacy
What problem does this paper attempt to address?